Cambridge, UK, 23rd February 2021: Chesterford Research Park is delighted to confirm the expansion of Camena Bioscience within the Science Village Building at the Park. The developer of an industry-leading DNA synthesis technology has renewed its existing lease for a further five years and in tandem taken an additional 1,993 sq ft adjoining suite on the same terms.
News
Ahead of the Chancellor’s Budget on 3rd March 2021, Cambridge Tax Partner Hannah Simoes and Deloitte experts give their key predictions for the event. The UK’s regions continue as an expected area of focus in this Budget.
Economic outlook
Ian Stewart, chief economist, said:
Stevenage Bioscience Catalyst (SBC) has launched a free accelerator programme to give data-focussed biotech start-ups the skills they need to get potential new drugs and therapies
to market more quickly.
A first of its kind virtual platform - ‘UK Healthcare Pavilion’ - that showcases the very best of UK healthcare and life sciences, has been launched.
The site provides news, insights, and interviews from a variety of key opinion leaders and policy makers, offering their views on topical subjects in the sector and showcasing the strengths the UK has to offer.
A team of Discovery Park scientists researching human neurological and psychiatric health conditions is expanding research opportunities for its Kent-based team in mainland Europe, by opening an additional laboratory in Poland.
The 2020 annual report for the Centre for Behaviour Change (CBC) is now available.
AMSBIO has introduced a collection of mutated SARS-CoV-2 spike proteins and recombinant antigens for the new virus variants - B.1.1.7 and B.1.351. These reagents can be used by researchers to evaluate the efficacy of the antibodies and identify targets for development of improved therapeutic drugs and vaccines.
Business clusters in the Oxford-Cambridge Arc region have strongly welcomed the government’s announcement today that it will identify the needs to propel the Arc’s innovation-led economy.
CAMBRIDGE, MASS., and LONDON – February 16, 2021 – Centessa Pharmaceuticals (“Centessa”) launched today as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs. Centessa’s asset-centric R&D model applied at scale has assembled best-in-class or first-in-class assets, each of which is led by specialized teams committed to accelerate development and reshape the traditional drug development process.
Cambridge, UK, 15 February 2021: Chesterford Research Park is delighted to welcome material research company Superdielectrics to the Park’s prestigious Science Village.